NeuroBo Pharmaceuticals, Inc. ( NRBO) Stock. Should you Buy or Sell? $ 0.28
-0.02 (-6.40 %)
NeuroBo Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | NRBO |
| Price | $0.28 |
| Beta | -0.474 |
| Volume Avg. | $79.76 thousand |
| Market Cap | $7.57 M |
| 52 Week Range | $0.247 - $4.289 |
NeuroBo Pharmaceuticals, Inc. opened the day at $0.28 which is -6.40 % on yesterday's close. NeuroBo Pharmaceuticals, Inc. has a 52 week high of $4.289 and 52 week low of $0.247, which is a difference of $4.042. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $7.57 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy NeuroBo Pharmaceuticals, Inc. for $7.57 M, it would take 15 years to get your money back. NeuroBo Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
NeuroBo Pharmaceuticals, Inc. Stock Forecast - Is NeuroBo Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Strong Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.295 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing NeuroBo Pharmaceuticals, Inc.
| Price Book Value Ratio | 0.833 | Price To Book Ratio | 0.833 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -0.295 |
How liquid is NeuroBo Pharmaceuticals, Inc.
| Current Ratio | 8.068 |
| Quick Ratio | 7.085 |
Debt
| Debt Ratio | 0.124 | Debt Equity Ratio | 0.141 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about NeuroBo Pharmaceuticals, Inc.
The stock price of NeuroBo Pharmaceuticals Inc (NASDAQ: NRBO) increased by over 40% pre-market today. This is why it happened.
Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Right Now?
The stock price of Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) increased by over 6% yesterday. This is why it happened.
There's loads of hot penny stocks worth checking in on today and we're taking a look at what some of the top movers are doing! The post Hot Penny Stocks: Why NEW, ARDX, WTRH, GSAT and NRBO Are Moving Today appeared first on InvestorPlace.
BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced the closing of its previously announced registered direct offering of 4,307,693 shares of the Company's common stock, at a purchase price of $3.25 per share. In a concurrent private placement, the Company issued to the investors in the registered direct offering unregistered warrants to purchase up to 4,307,693 shares of the Company's common stock.
About NeuroBo Pharmaceuticals, Inc.
Description :
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
